Drug Makers Catch FDA’s Drift, Look to Rid Processes of Variability

FDA officials say that drug manufacturers need to have better trending and monitoring programs in place to detect process drift in drug manufacture. They note that many of the controls needed to prevent process drift are already embodied in existing GMP regulations but are underutilized.

More from Archive

More from Pink Sheet